Our work suggests MeCP2 uses a different molecular mechanism to drive tumor progression in CRC: MeCP2 binds to SPI1 and aids its recruitment to the ZEB1 promoter, which in turn, affects ZEB1 expression at the transcription level. This evidence concerns the gene ZEB1 and colorectal carcinoma.